Adult human mesenchymal stromal cells and the treatment of graft versus host disease

Figures & data

Table 1 Mesenchymal stromal cell trials in acute graft versus host disease*

Authors	Phase	n	Dose	CR (%)	PR (%)	NR (%)	OS	Donor source
Ringden et al^Citation65	1	8	Variable	6 (75)	–	2 (25)	5 2–3 years	2 HLA ID siblings, 6 haploidentical family members
Fang et al^Citation66	1	6	1 × 10^6/kg × 1	5 (83)	–	1 (16.7)	4 40 months	Third party
Le Blanc et al^Citation50	2	55	Variable	30 (54.5)	9 (16.40)	16 (29.1)	52% for CR 16% for PR, NR	Third party
Von Bonin et al^Citation67	1	13	0.9 × 10^6/kg × 2	2 (15)	5 (38)	6 (46)	31% at 257 days	Third party
Kebriaei et al^Citation68	2	31	2 versus 8 × 10^6/kg × 2	24 (77)	5 (16)	2 (6.5)	NS	Third party
Perez-Simon et al^Citation69	1	10	2 × 10^6/kg × variable	1 (10)	6 (60)	3 (30)	20% at final follow-up	Various
Herrmann et al^Citation63	1	12	2 × 10^6/kg × 2–4	7 (58)	4 (38)	3 (30)	55% at 36 months	Haploidentical family members or third party
Muroi et al^Citation70	1	14	2 × 10^6/kg × 8	12 (86)	1 (7)	1 (7)	57% at 24 months	Third party

Notes:

* Published trials of mesenchymal stromal cells in acute graft versus host disease in peer-reviewed journals. Compassionate use reports are not included.

Abbreviations: NS, not stated; CR, complete response; OS, overall survival; PR, partial response; NR, no response; HLA ID, human leucocyte antigen identical.

Table 2 Mesenchymal stromal cell trials in chronic graft versus host disease*

Authors	Phase	n	Dose	CR (%)	PR (%)	NR (%)	OS	Donor BM source
Zhang et al^Citation71	1	12	Various × 3	3 (25)	6 (50)	3 (25)	77.7 at 2 years	Various
Weng et al^Citation72	1	19	0.6 × 10^6/kg × 1	4 (21)	10 (57.6)	5 (28.8)	75% (NS)	Third party
Zhou et al^Citation57	1	4	1–2 × 10^6/kg × 4–8	0	4 (100)	0	100% at 14–23 months	Third party
Perez-Simon et al^Citation69	1/2	8	2 × 10^6/kg × variable	1 (12)	4 (37)	4 (50)	2/8 at 5–12 months	Various
Herrmann et al^Citation63	1	7	2 × 10^6/kg × various	1 (12)	3 (43)	4 (57)	50% at 8 months	Various

Note:

* Published trials of mesenchymal stromal cells in chronic graft versus host disease in peer-reviewed journals.

Abbreviations: BM, bone marrow; NS, not stated; CR, complete response; OS, overall survival; PR, partial response; NR, no response.

RingdenOUzunelMRasmussonIMesenchymal stem cells for treatment of therapy-resistant graft-versus-host diseaseTransplantation2006811390139716732175

 PubMed Web of Science ®Google Scholar

FangBSongYLiaoLZhangYZhaoRCFavorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host diseaseTransplant Proc2007393358336218089385

 PubMed Web of Science ®Google Scholar

Le BlancKFrassoniFBallLMesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II studyLancet20083711579158618468541

 PubMed Web of Science ®Google Scholar

von BoninMStolzelFGoedeckeATreatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing mediumBone Marrow Transplant20094324525118820709

 PubMed Web of Science ®Google Scholar

KebriaeiPIsolaLBahceciEAdult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host diseaseBiol Blood Marrow Transplant20091580481119539211

 PubMed Web of Science ®Google Scholar

Perez-SimonJALopez-VillarOAndreuEJMesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trialHaematologica2011961072107621393326

 PubMed Web of Science ®Google Scholar

HerrmannRSturmMShawKMesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 studyInt J Hematol20129518218822183779

 PubMed Web of Science ®Google Scholar

MuroiKMiyamuraKOhashiKUnrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II studyInt J Hematol20139820621323860964

 PubMed Web of Science ®Google Scholar

ZhangLSLiuQFHuangKZhangYFanZPHuangSLMesenchymal stem cells for treatment of steroid-resistant chronic graft-versus-host diseaseZhonghua Nei Ke Za Zhi200948542546 Chinese19957792

 PubMedGoogle Scholar

WengJYDuXGengSXMesenchymal stem cell as salvage treatment for refractory chronic GVHDBone Marrow Transplant2010451732174020818445

 PubMed Web of Science ®Google Scholar

ZhouHGuoMBianCEfficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical reportBiol Blood Marrow Transplant20101640341219925878

 PubMed Web of Science ®Google Scholar